| Literature DB >> 33934590 |
Ilaria Stramazzo1,2, Marco Centanni1,2, Camilla Virili1.
Abstract
Entities:
Mesh:
Year: 2021 PMID: 33934590 PMCID: PMC8090460 DOI: 10.3803/EnM.2021.981
Source DB: PubMed Journal: Endocrinol Metab (Seoul) ISSN: 2093-596X
Changes in the Patient’s Biochemical and Clinical Features over Time
| Diagnosis of HT (23 yr) | Onset of orbitopathy (36 yr) | 3 Months after starting GFD | 6 Months after starting GFD | |
|---|---|---|---|---|
| TSH, mIU/L (normal range, 0.35–4.94) | 0.52 | 3.5 | 3.98 | 3.45 |
| FT4, ng/dL (normal range, 0.7–1.48) | 0.9 | 0.8 | 1 | 1.2 |
| TG Ab, IU/mL (<100) | 774 | 756 | 1.533 | - |
| TPO Ab, IU/mL (<16) | 461 | 549 | 651 | - |
| TRAb, IU/L (<1.2) | - | 3.4 | <1.2 | <1.2 |
| tTG Ab IgA, IU/mL (<16) | 31 | 25 | <16 | <16 |
| Eyelid aperture (right eye), mm | - | 12 | - | 10 |
HT, Hashimoto thyroiditis; GFD, gluten-free diet; TSH, thyroid-stimulating hormone; FT4, free thyroxine; TG Ab, anti-thyroglobulin antibody; TPO Ab, anti-thyroperoxidase antibody; TRAb, anti-TSH receptor antibody; tTG Ab IgA, anti-transglutaminase immunoglobulin A antibody.